Dr. Smith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Summary
- Dr. David Smith is an oncologist in Ann Arbor, MI and is affiliated with the University of Michigan Medical Center and Michigan Medicine. He received his medical degree from University of Washington School of Medicine and has been in practice 32 years. He specializes in genitourinary oncology and is experienced in clinical trials, prostate and bladder cancer, and testicular neoplasms.
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1989 - 1992
- University of WashingtonResidency, Internal Medicine, 1985 - 1988
- University of Washington School of MedicineClass of 1985
Certifications & Licensure
- MI State Medical License 1995 - 2027
- PA State Medical License 1992 - 1996
- NC State Medical License 1990 - 1995
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- 803 citationsIntegrative clinical genomics of advanced prostate cancer.Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro
Cell. 2015-05-21 - 291 citationsErratum: Integrative Clinical Genomics of Advanced Prostate CancerDan R. Robinson, Eliezer M. Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J. Lonigro
Cell. 2015-07-18 - 9288 citationsSafety, activity, and immune correlates of anti-PD-1 antibody in cancer.Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David Smith
The New England Journal of Medicine. 2012-06-27
Journal Articles
- Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer ImmunotherapyDavid Smith, Sarah Yentz, Biodrugs
Press Mentions
- David Smith Retires with a Legacy of Compassionate Patient CareOctober 16th, 2024
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: